PCD24: CONJOINT ANALYSIS COMPARING PREFERENCES FOR TREATMENT OUTCOMES IN HEART FAILURE AND HEALTHY PATIENTS: LONGEVITY VERSUS SYMPTOM RELIEF  by Oates, MB et al.
76 Abstracts
PCD24
CONJOINT ANALYSIS COMPARING 
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Congestive heart failure (CHF) affects nearly 5 million
Americans with over 400,000 new cases diagnosed annu-
ally. Total annual costs of care for CHF are estimated be-
tween $20–$40 billion. The CHF syndrome is character-
ized by functional limitations and poor Quality of Life
(QOL). Therapeutic options are thought to include the
ability to either extend life or improve QOL. The balance
of QOL versus survival issues among CHF patients is of
critical importance in prescribing appropriate therapy.
OBJECTIVE: The purpose of this study was to compare
CHF and healthy patients on their preferences for ther-
apy outcomes, evaluating their desire for improved qual-
ity of life versus survival. METHODS: Fifty-one CHF pa-
tients and 47 control subjects (matched for age, gender,
and race) were studied using full-profile conjoint analysis
to determine preferences for treatment outcomes. Sub-
jects rated 16 treatment outcome profiles, consisting of 4
attributes (tiredness, shortness of breath, depression, and
survival) varied across 4 severity levels. Part-worths (util-
ities) and importance weights were calculated for each at-
tribute to determine their relative contribution to the rat-
ing decision using standard conjoint analysis techniques.
RESULTS: Part-worths and importance weights were sig-
nificantly different for shortness of breath and depression
between patients and control subjects. Symptom-sensitive
(n  33) and survival-sensitive (n  17) treatment out-
come preference segments were identified within the
CHF patient group. Importance weights for symptom-
sensitive vs. survival-sensitive patients were: tiredness
0.30  0.10 vs. 0.16  0.09 (P  0.01); shortness of
breath 0.26  0.08 vs. 0.21  0.08 (P  0.07); depres-
sion 0.26  0.09 vs. 0.19  0.09 (P  0.01); and sur-
vival 0.18  0.07 vs. 0.43  0.11 (P  0.01). There were
no significant demographic predictors of which treatment
outcome preference segment a patient belonged. Control
subjects did not display preference segmentation. CON-
CLUSIONS: In this study, CHF patients were found to
be clustered into two subgroups: symptom-sensitive ver-
sus survival-sensitive in a manner suggesting that treat-
ment outcomes of improved symptoms were more impor-
tant to some patients than longer survival. A full
understanding of these individual preferences has impor-
tant implications for the prescribing of therapy for pa-
tients.
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SYSTEMATIC REVIEW EVIDENCE ON TREATING 
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Hypertension is very common, occurring in over 50% of
older people, and is a major risk factor for death from
stroke, congestive heart failure and coronary heart dis-
ease. Antihypertensive drug therapy is the mainstay of
treatment for hypertension. OBJECTIVE: The purpose
was to review the existing evidence from systematic re-
views and meta-analyses on the benefits of drug treat-
ment of hypertension in older people and to compare
the quality and results of individual reviews. METH-
ODS: Studies included were systematic reviews of drug
therapy for hypertension in older adults with a sub-
stantial literature search, appropriate inclusion criteria,
validity assessment, details of studies, and appropriate
pooling. The databases searched were Medline, Co-
chrane Library, HealthStar, Embase, and DARE, years
1993–1999. Quality assessment and data extraction
were performed independently by two reviewers. Out-
comes of interest were overall mortality, stroke morbid-
ity and mortality, CHD morbidity and mortality, and
cardiovascular morbidity and mortality. RESULTS: Ten
systematic reviews met inclusion criteria. Antihyperten-
sive drug therapy was associated with significant reduc-
tions in overall mortality, and mortality due to stroke,
coronary heart disease (CHD), and all cardiovascular
causes. To prevent one cerebrovascular event in the over
60s would mean treating 50 patients for five years. The
quality scores for the ten reviews ranged from 2.4 to 6.9
(0 to 7 possible), with the majority of the studies achiev-
ing a score of five or greater. The results of the meta-
analyses showed similar reductions in morbidity and
mortality, with the exception of those analysing individ-
ual drugs or age group. CONCLUSIONS: Treatment of
hypertension in older people reduces cardiovascular mor-
bidity and mortality by approximately 33%. The quality
differences between systematic reviews did not alter the
results.
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OBJECTIVES: To estimate the burden of hypertension to
a Fortune 500 employer and to assess patient adherence
to prescribed medications. METHODS: The prevalence
of hypertension, resources utilized, and direct costs in-
